Polymeric nanocarriers and nanoreactors: A survey of possible therapeutic applications

Current Pharmaceutical Design

Volumn 18, Issue 18, 2012, Pages 2622-2643

  Onaca Fischer, Ozana ^a   Liu, Juan ^a   Inglin, Mark ^a   Palivan, Cornelia G ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cancer; Drug delivery; Nanoreactors; Neurodegenerative diseases; Polymeric nanocarriers

Indexed keywords

ELLAGIC ACID; GLUCOSE OXIDASE; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOSPHERE; POLYGLACTIN; POLYMER; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIODEGRADABILITY; BIODEGRADATION; BLOOD BRAIN BARRIER; CELL DIVISION; CELL ORGANELLE; CELL VACUOLE; CELLULAR DISTRIBUTION; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DEGENERATIVE DISEASE; DEGRADATION; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPID PEROXIDATION; MICELLE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NANOENCAPSULATION; NANOREACTOR; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; REACTOR; REACTOR DESIGN; STROKE;

EID: 84862521475     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800492822     Document Type: Article

References (221)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007; 2: 751-60.
2. Farokhzad OC, Langer R. Impact of Nanotechnology on Drug Delivery. ACS Nano 2009; 3: 16-20.
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther 2007; 83: 761-769.
4. Palivan C, Onaca O, Delcea M, Itel F, and Meier W Proteinpolymer nanoreactors for medical applications. DOI: 10.1039/C1CS15240H.
5. Balasubramanian V, Onaca O, Enea R, Hughes DW, Palivan CG. Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Expert Opin Drug Deliv 2010; 7: 63-78.
6. Patil ML, Zhang M, Minko T. Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing. ACS Nano 2011; 5: 1877-87.
7. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chemical Society Reviews 2011; 40:3638-55.
8. Cabane E, Malinova V, Meier W. Synthesis of Photocleavable Amphiphilic Block Copolymers: Toward the Design of Photosensitive Nanocarriers. Macromol Chem Phys 2010; 211: 1847-56.
9. Grove TZ, Osuji CO, Forster JD, Dufresne ER, Regan L. Stimuli- Responsive Smart Gels Realized via Modular Protein Design. J Am Chem Soc 2010; 132: 14024-6.
10. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles selfassembled from a biodegradable copolymer. Nat Mater 2006; 5: 791-6.
11. Egli S, Nussbaumer MG, Balasubramanian V, et al. Biocompatible Functionalization of Polymersome Surfaces: A New Approach to Surface Immobilization and Cell Targeting Using Polymersomes. J Am Chem Soc 2011; 133: 4476-83.
12. Modi G, Pillay V, Choonara YE, Ndesendo VMK, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009; 88: 272-85.
13. Barreto JA, O'Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: Applications in Cancer Imaging and Therapy. Adv Mat 2011; 23: H18-H40.
14. Mayeux R. Epidemiology of neurodegeneration. Ann Rev Neurosci 2003; 26: 81-104.
15. Robichaud AJ. Approaches to Palliative Therapies for Alzheimers Disease. Curr Top Med Chem 2006; 6: 553-68.
16. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci 2010; 1184: 154-72.
17. Egli S, Schlaad H, Bruns N, Meier W. Functionalization of Block Copolymer Vesicle Surfaces. Polymers 2011; 3: 252-80.
18. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
19. Tanner P, Baumann P, Enea R, Onaca O, Palivan C, Meier W. Polymeric Vesicles: From Drug Carriers to Nanoreactors and Artificial Organelles. Acc Chem Res 2011; 44: 1039-49.
20. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent. Pharm Res 1997; 14: 1568-73.
21. Yin Win K, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713-22.
22. Kita-Tokarczyk K, Grumelard J, Haefele T, Meier W. Block copolymer vesicles-using concepts from polymer chemistry to mimic biomembranes. Polymer 2005; 46: 3540-63.
23. Palivan C, Vebert C, Axthelm F, Meier W. Responsive selfassembled nanostructures. Nanotechnol Biol Med 2007; 32: 467-92.
24. Onaca O, Enea R, Hughes DW, Meier W. Stimuli-Responsive Polymersomes as Nanocarriers for Drug and Gene Delivery. Macromol Biosci 2009; 9: 129-39.
25. Haruma K. Functional polymer microspheres. Prog Polym Sci 2000; 25: 1171-210.
26. E. Bayer WR. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Application, (M. Harris, Ed.) Plenum Press New York 1992: 325.
27. Knutton S. Studies of membrane fusion. III. Fusion of erythrocytes with polyethylene glycol. J Cell Sci 1979; 36: 61-72.
28. Wojcieszyn JW, Schlegel RA, Lumley-Sapanski K, Jacobson KA. Studies on the mechanism of polyethylene glycol-mediated cell fusion using fluorescent membrane and cytoplasmic probes. J Cell Biol 1983; 96: 151-9.
29. Shao K, Huang R, Li J, Han L, Ye L, Lou J, Jiang C. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 2010; 147: 118-26.
30. Zhang P, Hu L, Wang Y, Wang J, Feng L, Li Y. Poly(ε- caprolactone)-Block-poly(ethyl Ethylene Phosphate) Micelles for Brain-Targeting Drug Delivery: In vitro and In vivo Valuation. Pharm Res 2010; 27: 2657-69.
31. Adams DJ, Adams S, Atkins D, Butler MF, Furzeland S. Impact of mechanism of formation on encapsulation in block copolymer vesicles. J Control Release 2008; 128: 165-70.
32. Babic M, Horák D, Trchová M, et al. Poly(l-lysine)-Modified Iron Oxide Nanoparticles for Stem Cell Labeling. Bioconjugate Chem 2008; 19: 740-50.
33. Zhu Y, Zhang G, Yang H, Hong X. Influence of surfactants on the parameters of polylactide nanocapsules containing insulin. Journal of Surfactants and Detergents 2005; 8: 353-8.
34. Palivan CG, Vebert C, Axthelm F, Meier W. Responsive Self- Assembled Nanostructures. Crc Press-Taylor & Francis Group 2007.
35. Li Y, Lokitz BS, Armes SP, McCormick CL. Synthesis of Reversible Shell Cross-Linked Micelles for Controlled Release of Bioactive Agents†. Macromolecules 2006; 39: 2726-8.
36. Nanoparticles for Drug Delivery: Review of the Formulation and Process Difficulties Illustrated by the Emulsion-Diffusion Process. J Nanosci Nanotechnol 2006; 6: 2664-81.
37. Tan Y, Xu K, Li L, Liu C, Song C, Wang P. Fabrication of Size- Controlled Starch-Based Nanospheres by Nanoprecipitation. ACS Applied Materials & Interfaces 2009; 1: 956-9.
38. Olivier J-C. Drug Transport to Brain with Targeted Nanoparticles. NeuroRX 2005; 2: 108-19.
39. Calvo P, Gouritin B, Chacun H, et al. Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery. Pharm Res 2001; 18: 1157-66.
40. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surface B 2010; 75: 1-18.
41. Qian F, Cui F, Ding J, Tang C, Yin C. Chitosan Graft Copolymer Nanoparticles for Oral Protein Drug Delivery: Preparation and Characterization. Biomacromolecules 2006; 7: 2722-7.
42. Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul 2005; 22: 773-85.
43. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J Control Release 2004; 96: 37-53.
44. Griset AP, Walpole J, Liu R, Gaffey A, Colson YL, Grinstaff MW. Expansile Nanoparticles: Synthesis, Characterization, and in vivo Efficacy of an Acid-Responsive Polymeric Drug Delivery System. J Am Chem Soc 2009; 131: 2469-71.
45. Xu P, Van Kirk EA, Murdoch WJ, et al. Anticancer Efficacies of Cisplatin-Releasing pH-Responsive Nanoparticles. Biomacromolecules 2006; 7: 829-35.
46. Musyanovych A, Landfester K. Synthesis of poly (butylcyanoacrylate) nanocapsules by interfacial polymerization in miniemulsions for the delivery of DNA molecules. Prog Coll Pol Sci S 2008: 120-7.
47. Moraes CM, de Matos AP, de Paula E, Rosa AH, Fraceto LF. Benzocaine loaded biodegradable poly-(d,l-lactide-co-glycolide) nanocapsules: factorial design and characterization. Mat Sci Engineering: B 2009; 165: 243-6.
48. Sukhorukov GB, Donath E, Davis S, et al. Stepwise polyelectrolyte assembly on particle surfaces: a novel approach to colloid design. Polym Adv Technol 1998; 9: 759-67.
49. Prego C, Fabre M, Torres D, Alonso M. Efficacy and Mechanism of Action of Chitosan Nanocapsules for Oral Peptide Delivery. Pharm Res 2006; 23: 549-56.
50. Schaffazick SR, Siqueira IR, Badejo AS, et al. Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver. Eur J Pharm Biopharm 2008; 69: 64-71.
51. Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J Biomed Mat Res 1999; 47: 568-76.
52. Wang Y, Bansal V, Zelikin AN, Caruso F. Templated synthesis of single-component polymer capsules and their application in drug delivery. Nano Lett 2008; 8: 1741-5.
53. Delcea M, Yashchenok A, Videnova K, Kreft O, Möhwald H, Skirtach AG. Multicompartmental Micro- and Nanocapsules: Hierarchy and Applications in Biosciences. Macromol Biosci 2010; 10: 465-74.
54. Fresta M, Cavallaro G, Giammona G, Wehrli E, Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996; 17: 751-758.
55. Liu TY, Liu KH, Liu DM, Chen SY, Chen IW. Temperature- Sensitive Nanocapsules for Controlled Drug Release Caused by Magnetically Triggered Structural Disruption. Adv Funct Mat 2009; 19: 616-23.
56. Sauer M, Streich D, Meier W. pH-Sensitive Nanocontainers. Adv Mat 2001; 13: 1649-1651.
57. Lee SH, Choi SH, Kim SH, Park TG. Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: Swelling induced physical disruption of endosome by cold shock. J Control Release 2008; 125: 25-32.
58. Discher DE, Eisenberg A. Polymer Vesicles. Science 2002; 297: 967-73.
59. Lo CL, Lin SJ, Tsai HC, et al. Mixed micelle systems formed from critical micelle concentration and temperature-sensitive diblock copolymers for doxorubicin delivery. Biomaterials 2009; 30: 3961-70.
60. Chung JE, Yokoyama M, Okano T. Inner core segment design for drug delivery control of thermo-responsive polymeric micelles. J Control Release 2000; 65: 93-103.
61. Shuai X, Merdan T, Schaper AK, Xi F, Kissel T. Core-Cross- Linked Polymeric Micelles as Paclitaxel Carriers. Bioconjugate Chem 2004; 15: 441-8.
62. Tan JPK, Kim SH, Nederberg F, et al. Delivery of Anticancer Drugs Using Polymeric Micelles Stabilized by Hydrogen-Bonding Urea Groups. Macromol Rapid Commun 2010; 31: 1187-92.
63. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nano 2007; 2: 249-55.
64. Nakayama M, Okano T, Miyazaki T, Kohori F, Sakai K, Yokoyama M. Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. J Control Release 2006; 115: 46-56.
65. Tang Y, Liu SY, Armes SP, Billingham NC. Solubilization and Controlled Release of a Hydrophobic Drug Using Novel Micelle- Forming ABC Triblock Copolymers. Biomacromolecules 2003; 4: 1636-45.
66. Nardin C, Hirt T, Leukel J, Meier W. Polymerized ABA triblock copolymer vesicles. Langmuir 2000; 16: 1035-41.
67. Ranquin A, Versées W, Meier W, Steyaert J, Van Gelder P. Therapeutic Nanoreactors: Combining Chemistry and Biology in a Novel Triblock Copolymer Drug Delivery System. Nano Lett 2005; 5: 2220-4.
68. Balasubramanian V, Onaca O, Ezhevskaya M, Van Doorslaer S, Sivasankaran B, Palivan CG. A surprising system: polymeric nanoreactors containing a mimic with dual-enzyme activity. Soft Matter 2011; 7: 5595-603.
69. Du J, Armes SP. pH-Responsive Vesicles Based on a Hydrolytically Self-Cross-Linkable Copolymer. J Am Chem Soc 2005; 127: 12800-1.
70. Yan Q, Yuan J, Cai Z, Xin Y, Kang Y, Yin Y. Voltage-Responsive Vesicles Based on Orthogonal Assembly of Two Homopolymers. J Am Chem Soc 2010; 132: 9268-70.
71. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 2006; 116: 150-8.
72. Meng F, Zhong Z, Feijen J. Stimuli-Responsive Polymersomes for Programmed Drug Delivery. Biomacromolecules 2009; 10: 197-209.
73. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8: 473-80.
74. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008; 69: 1-9.
75. Kamphuis MMJ, Johnston APR, Such GK, et al. Targeting of Cancer Cells Using Click-Functionalized Polymer Capsules. J Am Chem Soc 2010; 132: 15881-3.
76. Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm 2008; 5: 496-504.
77. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009; 61: 428-37.
78. Broz P, Benito SM, Saw C, et al. Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Release 2005; 102: 475-88.
79. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008; 51: 246-52.
80. Christian NA, Milone MC, Ranka SS, et al. Tat-Functionalized Near-Infrared Emissive Polymersomes for Dendritic Cell Labeling. Bioconjugate Chemistry 2006; 18: 31-40.
81. Demirgoz D, Pangburn TO, Davis KP, Lee S, Bates FS, Kokkoli E. PR_b-targeted delivery of tumor necrosis factor-[small alpha] by polymersomes for the treatment of prostate cancer. Soft Matter 2009; 5: 2011-9.
82. Upadhyay KK, Bhatt AN, Mishra AK, et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010; 31: 2882-92.
83. Rieux L, Lubda D, Niederlander HA, Verpoorte E, Bischoff R. Fast, high-efficiency peptide separations on a 50-microm reversedphase silica monolith in a nanoLC-MS set-up. J Chromatogr A 2006; 1120: 165-72.
84. Walter E, Dreher D, Kok M, et al. Hydrophilic poly(dl-lactide-coglycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release 2001; 76: 149-68.
85. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002; 79: 123-35.
86. Muthu M. Nanoparticles based on PLGA and its co-polymer: An overview. Asian J Pharm 2009; 3: 266.
87. Prabha S, Labhasetwar V. Critical Determinants in PLGA/PLA Nanoparticle-Mediated Gene Expression. Pharm Res 2004; 21: 354-364.
88. Vij N, Min T, Marasigan R, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnol 2010; 8: 22.
89. Alyaudtin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro. J Drug Target 2001; 9: 209-21.
90. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles. Pharm Res 1997; 14: 325-8.
91. Kreuter J, Ramge P, Petrov V, et al. Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles. Pharm Res 2003; 20: 409-16.
92. Calvo P, Gouritin B, Villarroya H, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002; 15: 1317-26.
93. Ghosh A, Mandal AK, Sarkar S, Panda S, Das N. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci 2009; 84: 75-80.
94. Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008; 346: 160-8.
95. Sepideh Khoee SHaBG. Effects of hydrophobic drug-polyesteric core interactions on drug loading and release properties of poly(ethylene glycol)-polyester-poly(ethylene glycol) triblock core-shell nanoparticle. Nanotechnology; 18: 175602-11.
96. Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MNVR. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm 2007; 67: 361-9.
97. Dziubla TD, Karim A, Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release 2005; 102: 427-39.
98. Batrakova EV, Li S, Reynolds AD, et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjugate chemistry 2007; 18: 1498-506.
99. Simone EA, Dziubla TD, Discher DE, Muzykantov VR. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules 2009; 10: 1324-30.
100. Simone EA, Dziubla TD, Arguiri E, et al. Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm Res 2009; 26: 250-60.
101. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. The FASEB Journal 2009; 23: 1384.
102. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MNV. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target 2006; 14: 27-34.
103. Sharma G, Italia JL, Sonaje K, Tikoo K, Ravi Kumar MNV. Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: Evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats. J Control Release 2007; 118: 27-37.
104. Sonaje K, Italia J, Sharma G, Bhardwaj V, Tikoo K, Kumar M. Development of Biodegradable Nanoparticles for Oral Delivery of Ellagic Acid and Evaluation of Their Antioxidant Efficacy Against Cyclosporine A-Induced Nephrotoxicity in Rats. Pharm Res 2007; 24: 899-908.
105. Mahmud A, Xiong X-B, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target 2007; 15: 553-84.
106. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47: 113-31.
107. Rösler A, Vandermeulen GWM, Klok H-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53: 95-108.
108. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
109. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEGPLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Col Interface Sci 2011; 354: 116-23.
110. Zhang P, Hu L, Wang Y, Wang J, Feng L, Li Y. Poly(ε- caprolactone)-Block-poly(ethyl Ethylene Phosphate) Micelles for Brain-Targeting Drug Delivery: In vitro and In vivo Valuation. Pharm Res 2010; 27: 2657-69.
111. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids and Surfaces B 2008; 66: 274-80.
112. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 2006; 310: 213-9.
113. De Jong WH HW, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008; 29: 1912-9.
114. Wittemann A, Azzam T, Eisenberg A. Biocompatible polymer vesicles from biamphiphilic triblock copolymers and their interaction with bovine serum albumin. Langmuir 2007; 23: 2224-30.
115. Arifin DR, Palmer AF. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules 2005; 6: 2172-81.
116. Chen Q, Schönherr H, Vancso GJ. Block-Copolymer Vesicles as Nanoreactors for Enzymatic Reactions. Small 2009; 5: 1436-1445.
117. Grzelakowski M, Onaca O, Rigler P, Kumar M, Meier W. Immobilized protein-polymer nanoreactors. Small 2009; 5: 2545-8.
118. Lomas H, Massignani M, Abdullah KA, et al. Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery. Faraday Discuss 2008; 139: 143-59.
119. Kim Y, Tewari M, Pajerowski JD, et al. Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release 2009; 134: 132-40.
120. van Dongen SF, Nallani M, Cornelissen JJ, Nolte RJ, van Hest JC. A three-enzyme cascade reaction through positional assembly of enzymes in a polymersome nanoreactor. Chemistry 2009; 15: 1107-14.
121. Vriezema DM, Hoogboom J, Velonia K, et al. Vesicles and Polymerized Vesicles from Thiophene-Containing Rod-Coil Block Copolymers. Angew Chem 2003; 115: 796-800.
122. van Dongen SFM, Verdurmen WPR, Peters RJRW, Nolte RJM, Brock R, van Hest JCM. Cellular Integration of an Enzyme- Loaded Polymersome Nanoreactor. Angew Chem Int Ed 2010; 49: 7213-6.
123. Napoli A, Valentini M, Tirelli N, Muller M, Hubbell JA. Oxidation-responsive polymeric vesicles. Nat Mater 2004; 3: 183-9.
124. Kumar M, Grzelakowski M, Zilles J, Clark M, Meier W. Highly permeable polymeric membranes based on the incorporation of the functional water channel protein Aquaporin Z. Proc Nat Acad Sci 2007; 104: 20719-24.
125. Axthelm F, Casse O, Koppenol WH, Nauser T, Meier W, Palivan CG. Antioxidant Nanoreactor Based on Superoxide Dismutase Encapsulated in Superoxide-Permeable Vesicles. J Phys Chem B 2008; 112: 8211-7.
126. Balasubramanian V, Onaca O, Enea R, Hughes DW, Palivan CG. Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Expert Opin Drug Deliv 2010; 7: 63-78.
127. Onaca O, Hughes DW, Balasubramanian V, Grzelakowski M, Meier W, Palivan CG. SOD antioxidant nanoreactors: influence of block copolymer composition on the nanoreactor efficiency. Macromol Biosci 2010; 10: 531-8.
128. Nallani M, Benito S, Onaca O, et al. A nanocompartment system (Synthosome) designed for biotechnological applications. J Biotechnol 2006; 123: 50-9.
129. Graff A, Fraysse-Ailhas C, Palivan CG, et al. Amphiphilic Copolymer Membranes Promote NADH:Ubiquinone Oxidoreductase Activity: Towards an Electron-Transfer Nanodevice. Macromol Chem Phys 2010; 211: 229-38.
130. Graff A, Sauer M, Van Gelder P, Meier W. Virus-assisted loading of polymer nanocontainer. Proc Nat Acad Sci 2002; 99: 5064-8.
131. Koebnik R, Locher KP, Van Gelder P. Structure and function of bacterial outer membrane proteins: barrels in a nutshell. Mol Microbiol 2000; 37: 239-53.
132. Nardin C, Widmer J, Winterhalter M, Meier W. Amphiphilic block copolymer nanocontainers as bioreactors. Eur Phys J E 2001; 4: 403-10.
133. Tanner P, Onaca O, Balasubramanian V, Meier W, Palivan CG. Enzymatic Cascade Reactions inside Polymeric Nanocontainers: A Means to Combat Oxidative Stress. Chem Eur J 2011; 17: 4552-60.
134. Balasubramanian V, Ezhevskaya M, Moons H, et al. Structural characterization of a highly active superoxide-dismutase mimic. Phys Chem Chem Phys 2009; 11: 6778-87.
135. Kamat NP, Katz JS, Hammer DA. Engineering Polymersome Protocells. J Phys Chem Lett 2011; 2: 1612-23.
136. Dröge W. Oxidative stress and ageing: is ageing a cysteine deficiency syndrome? Phil Trans R Soc B 2005; 360: 2355.
137. Slemmer J, Shacka J, Sweeney M, Weber J. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem 2008; 15: 404-14.
138. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009; 7: 65-74.
139. Droege W. Oxidative Stress, Disease, Cancer In: Singh KK, ed.^eds. Imperial College Press: London 2006; pp. 885-95.
140. Lomri A. Role of reactive oxygen species and superoxide dismutase in cartilage aging and pathology. Fut Rheumatol 2008; 3: 381-92.
141. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A Prospective Study of Cigarette Smoking and Age-Related Macular Degeneration in Women. J Am Med Asso 1996; 276: 1141-6.
142. Tanriverdi H, Evrengul H, Kuru O, et al. Cigarette Smoking Induced Oxidative Stress may Impair Endothelial Function and Coronary Blood Flow in Angiographically Normal Coronary Arteries. Circ J 2006; 70: 593-9.
143. Rice-Evans CA, Diplock AT. Current status of antioxidant therapy. Free Radical Bio Med 1993; 15: 77-96.
144. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-58.
145. Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins, Leukotrienes and Essential Fatty Acids 2008; 79: 85-91.
146. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 2008; 36: 1304-8.
147. Duncan AJ, Heales SJR. Nitric oxide and neurological disorders. Molecular Aspects of Medicine 2005; 26: 67-96.
148. Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine 2009; 4: 541-55.
149. Andreas Reichel DJBuNJA. An Overview of In vitro Techniques for Blood-Brain Barrier Studies In: ed.^eds., Methods in Molecular Medicine. Humana Press, Inc: Totowa, NJ 2003; pp. 307-24.
150. Crone C, Olesen SP. Electrical resistance of brain microvascular endothelium. Brain Res 1982; 241: 49-55.
151. Urquhart B, Kim R. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharm 2009; 65: 1063-70.
152. Zhuang ZP, Kung MP, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44: 1905-14.
153. Smith QR. A review of blood-brain barrier transport techniques. Methods Mol Med 2003; 89: 193-208.
154. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity. J Bio Chem 1999; 274: 37111-6.
155. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting ß amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003; 60: 1685-91.
156. Salmaso S, Pappalardo JS, Sawant RR, et al. Targeting Glioma Cells in vitro with Ascorbate-Conjugated Pharmaceutical Nanocarriers. Bioconjugate Chemistry 2009; 20: 2348-55.
157. Shen J, Zhan C, Xie C, et al. Poly(ethylene glycol)-blockpoly(D,L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J Drug Target 2011; 19: 197-203.
158. Ren WH, Chang J, Yan CH, et al. Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma. Journal of Materials Science: Materials in Medicine 2010; 21: 2673-81.
159. Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell- Penetrating Peptide-Modified Block Copolymer Micelles Promote Direct Brain Delivery via Intranasal Administration. Pharm Res 2011: 1-10.
160. Zhao BJ, Ke XY, Huang Y, et al. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGRM- PTX) for the treatment of glioma in rats. J Drug Target 2011; 19: 382-90.
161. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
162. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 2009; 284: 6972.
163. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44-8.
164. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171-4.
165. Schroeder U, Sabel BA, Schroeder H. Diffusion enhancement of drugs by loaded nanoparticles in vitro. Prog Neuro-Psychoph 1999; 23: 941-9.
166. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 2003; 93: 151-60.
167. Celeste Roney PK, Arora V, Bennett M, et al. Feature Article: Polymeric Nanoparticulate Drug Delivery Through The Blood Brain Barrier Polym News 2005; 30: 311-21
168. Golde TE. Disease modifying therapy for AD?1. J Neurochem 2006; 99: 689-707.
169. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009; 17: 2950-62.
170. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimer Dis 2008; 13: 199-223.
171. Crowe A, Morgan E. Effects of chelators on iron uptake and release by the brain in the rat. Neurochem Res 1994; 19: 71-6.
172. Liu G, Men P, Harris PLR, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006; 406: 189-93.
173. Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-[beta] aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009; 455: 187-90.
174. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, et al. Inhibition of Amyloid β Protein Fibrillation by Polymeric Nanoparticles. J Am Chem Soc 2008; 130: 15437-43.
175. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG. Prophylaxis of Plasmodium falciparum Infection in a Human Challenge Model with WR 238605, a New 8-Aminoquinoline Antimalarial. Antimicrob Agents Ch 1998; 42: 1293-4.
176. Batrakova EV, Li S, Reynolds AD, et al. A Macrophage-Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry 2007; 18: 1498-1506.
177. Skaat H, Sorci M, Belfort G, Margel S. Effect of maghemite nanoparticles on insulin amyloid fibril formation: Selective labeling, kinetics, and fibril removal by a magnetic field. J Biomed Mats Res Part A 2009; 91A: 342-51.
178. Singh S, Singh M, Gambhir I. Nanotechnology for Alzheimer's disease detection. Digest J. Nanomater. Biostruct 2008; 3: 75-9.
179. Corti O, Hampe C, Darios F, Ibanez P, Ruberg M, Brice A. Parkinson's disease: from causes to mechanisms. C R Biol 2005; 328: 131-42.
180. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional Protein Delivery into Neurons Using Polymeric Nanoparticles. J Biol Chem 2009; 284: 6972-81.
181. Basso AS, Frenkel D, Quintana FJ, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Inves 2008; 118: 1532-45.
182. Reddy M, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide Dismutase-Loaded PLGA Nanoparticles Protect Cultured Human Neurons Under Oxidative Stress. App Biochem Biotechnol 2008; 151: 565-77.
183. Shibata N, Nagai R, Miyata S, et al. Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta Neuropathol 2000; 100: 275-84.
184. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. The FASEB Journal 2009; 23: 1384-95.
185. Marsh J, Senpan A, Hu G, et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomed 2007; 2: 533-43.
186. Piras AM, Dessy A, Chiellini F, et al. Polymeric nanoparticles for hemoglobin-based oxygen carriers. BBA Proteom 2008; 1784: 1454-61.
187. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
188. Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin Cancer Res 2008; 14: 1310-6.
189. Wang X, Wang Y, Chen ZG, Shin DM. Advances of cancer therapy by nanotechnology. Cancer Res Treatment 2009; 41: 1.
190. Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target 2007; 15: 553-84.
191. Chen ZG. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med 2010; 16: 594-602.
192. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
193. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
194. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Targeted nanoparticles for detecting and treating cancer. Drug Dev Res 2006; 67: 70-93.
195. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-15.
196. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomednanotechnol 2010; 6: 714-29.
197. Liu C, Chang K, Wang Y. A novel biodegradable amphiphilic diblock copolymers based on poly(lactic acid) and hyaluronic acid as biomaterials for drug delivery. J Polym Res 2010; 17: 459-69.
198. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, Boothman DA, Gao J. cRGD Functionalized Polymer Micelles for Targeted Doxorubicin Delivery. Angew Chem 2004; 116: 6483-7.
199. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001; 74: 295-302.
200. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxelincorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Brit J cancer 2005; 92: 1240-6.
201. Kim TY, Kim DW, Chung JY, et al. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle- Formulated Paclitaxel, in Patients with Advanced Malignancies. Clin Cancer Res 2004; 10: 3708-16.
202. Shin J, Shin K, Lee H, et al. Non invasive Transdermal Delivery Route Using Electrostatically Interactive Biocompatible Nanocapsules. Adv Mat 2010; 22: 739-43.
203. Ahmed F, Pakunlu RI, Srinivas G, et al. Shrinkage of a Rapidly Growing Tumor by Drug-Loaded Polymersomes: pH-Triggered Release through Copolymer Degradation. Mol Pharm 2006; 3: 340-50.
204. Mi Y, Liu Y, Feng S-S. Formulation of Docetaxel by folic acidconjugated d-[alpha]-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy. Biomaterials 2011; 32: 4058-66.
205. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38- incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2011; 63: 184-92.
206. Talelli M, Iman M, Varkouhi AK, Rijcken CJF, Schiffelers RM, Etrych T, Ulbrich K, van Nostrum CF, Lammers T, Storm G, Hennink WE. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 2010; 31: 7797-804.
207. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 2005; 4: 255-260.
208. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II Study of CT- 2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. J Clin Oncol 2004; 22: 4523-31.
209. Bhatt R, de Vries P, Tulinsky J, Bellamy G, Baker B, Singer JW, Klein P. Synthesis and in vivo Antitumor Activity of Poly(lglutamic acid) Conjugates of 20(S)-Camptothecin. J Med Chem 2002; 46: 190-3.
210. Vasey PA, Kaye SB, Morrison R, et al. Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl) methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents-Drug-Polymer Conjugates. Clin Cancer Res 1999; 5: 83-94.
211. Seymour LW, Ferry DR, Anderson D, et al. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin. J Clin Oncology 2002; 20: 1668-76.
212. Xiong X-B, Falamarzian A, Garg SM, Lavasanifar A. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. J Control Release 2011; 155: 248-61.
213. Kanayama N, Fukushima S, Nishiyama N, et al. A PEG-Based Biocompatible Block Catiomer with High Buffering Capacity for the Construction of Polyplex Micelles Showing Efficient Gene Transfer toward Primary Cells. ChemMedChem 2006; 1: 439-44.
214. Guo S, Huang Y, Zhang W, et al. Ternary complexes of amphiphilic polycaprolactone-graft-poly (N,N-dimethylaminoethyl methacrylate), DNA and polyglutamic acid-graft-poly(ethylene glycol) for gene delivery. Biomaterials 2011; 32: 4283-92.
215. Canine BF, Wang Y, Ouyang W, Hatefi A. Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. J Control Release 2011; 151: 95-101.
216. Cun D, Jensen DK, Maltesen MJ, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. Eur J Pharm Biopharm 2011; 77: 26-35.
217. Jain R, Nabar S, Dandekar P, Patravale V. Micellar Nanocarriers: Potential Nose-to-Brain Delivery of Zolmitriptan as Novel Migraine Therapy. Pharm Res 2010; 27: 655-64.
218. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine: Nanotechnology, Biol Med 2010; 6: 689-97.
219. De Vocht C, Ranquin A, Willaert R, et al. Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE. J Control Release 2009; 137: 246-54.
220. Broz P, Driamov S, Ziegler J, Ben-Haim N, Marsch S, Meier W, Hunziker P. Toward intelligent nanosize bioreactors: a pHswitchable, channel-equipped, functional polymer nanocontainer. Nano Lett 2006; 6: 2349-53.
221. Ben-Haim N, Broz P, Marsch S, Meier W, Hunziker P. Cell- Specific Integration of Artificial Organelles Based on Functionalized Polymer Vesicles. Nano Lett 2008; 8: 1368-73.